Noman Muhammad Zaeem, Messai Yosra, Carré Thibault, Akalay Intissar, Méron Marine, Janji Bassam, Hasmim Meriem, Chouaib Salem
Institut National de la Santé et de la Recherche Médicale Unité 753, Villejuif, France.
Crit Rev Immunol. 2011;31(5):357-77. doi: 10.1615/critrevimmunol.v31.i5.10.
Hypoxia, a common feature of solid tumors and one of the hallmarks of tumor microenvironment, favors tumor survival and progression. Although hypoxia has been reported to play a major role in the acquisition of tumor resistance to cell death, the molecular mechanisms that control the survival of hypoxic cancer cells and the role of hypoxic stress in shaping the cross talk between immune cells and stroma components are not fully elucidated. Recently, several lines of investigation are pointing to yet another ominous outcome of hypoxia in the tumor microenvironment involving suppression of antitumor immune effector cells and enhancement of tumor escape from immune surveillance. Although the identification of tumor-associated antigens provided a new arsenal of approaches to enhance antigen-specific response, the immunotherapy approaches that are currently used in the clinic have only limited success. In fact, tumor stroma components including hypoxia are engaged in an active molecular cross talk that has serious implications for immunological recognition of tumor in shaping the microenvironment. In this review, we will focus on the impact of hypoxia on the regulation of the antitumor response and the subsequent tumor progression. We will also in particular discuss data that indicate that manipulation of hypoxic stress may represent an innovative strategy for a better immunotherapy of cancer.
缺氧是实体瘤的常见特征,也是肿瘤微环境的标志之一,有利于肿瘤的存活和进展。尽管已有报道称缺氧在肿瘤获得细胞死亡抗性中起主要作用,但控制缺氧癌细胞存活的分子机制以及缺氧应激在塑造免疫细胞与基质成分之间相互作用中的作用尚未完全阐明。最近,多项研究表明肿瘤微环境中的缺氧还有另一个不祥后果,即抑制抗肿瘤免疫效应细胞并增强肿瘤逃避免疫监视的能力。尽管肿瘤相关抗原的鉴定提供了一系列增强抗原特异性反应的新方法,但目前临床使用的免疫治疗方法仅取得了有限的成功。事实上,包括缺氧在内的肿瘤基质成分参与了活跃的分子相互作用,这对塑造微环境中肿瘤的免疫识别具有严重影响。在本综述中,我们将重点关注缺氧对抗肿瘤反应调节及随后肿瘤进展的影响。我们还将特别讨论一些数据,这些数据表明操纵缺氧应激可能代表一种更好的癌症免疫治疗创新策略。